Alexion to present 16 abstracts on hypophosphatasia and hypoparathyroidism at ASBMR 2026 Annual Meeting
Posted on October 12, 2026
Alexion, AstraZeneca Rare Disease, will give 16 presentations, three of them oral, covering hypophosphatasia (HPP), chronic hypoparathyroidism (HypoPT) and early research at the American Society for Bone and Mineral Research Annual Meeting in Boston, Massachusetts, from 9 to 12 October 2026.
The headline presentations are results from the HICKORY Phase III trial of efzimfotase alfa (ALXN1850) in treatment naïve adolescents and adults with HPP, and skeletal data from the CALYPSO Phase III trial of eneboparatide, an investigational parathyroid hormone 1 receptor agonist, in adults with HypoPT. The company says the HICKORY findings add to the evidence that efzimfotase alfa could improve outcomes across a broad group of people with HPP.
Gianluca Pirozzi, senior vice president and head of development, regulatory and safety at Alexion, said the 16 presentations show the breadth of the company’s research in HPP and HypoPT, two rare, multisystem diseases that can profoundly affect daily life. He said HICKORY, the first Phase III trial to include patients with adult onset disease, should reinforce efzimfotase alfa’s potential to ease treatment burden and raise expectations of care, while real world evidence will shed light on the impact of HPP. Together with new bone data from CALYPSO in HypoPT, he said, the programme reflects Alexion’s commitment to innovations that meet the needs of patients and their families.
Alexion presentations at the 2026 ASBMR Annual Meeting
Hypophosphatasia
| Lead author | Abstract title | Presentation details |
|---|---|---|
| Peroutka, C. | Genetic Characterization and Clinical Manifestations in Adults with Hypophosphatasia in the United States | Welcome Reception and Plenary Poster Session, Abstract #FRI-465, 9 October 2026, 5:30 to 7:15 PM ET; Poster Session I, Abstract #SAT-465, 10 October 2026, 2:00 to 3:30 PM ET |
| Moss, K. | Understanding Disease Burden and Characterizing Diagnosis, Assessment, and Management of Adults with Hypophosphatasia in the UK: A Delphi Study | Late Breaking Poster Session I, Abstract #SAT-551, 10 October 2026, 2:00 to 3:30 PM ET |
| Dahir, K. | Assessing the compliance, usability, health insights, and perceived value from an at-home digital assessment toolkit for adults with hypophosphatasia: a multicenter observational study | Poster Session I, Abstract #SAT-489, 10 October 2026, 2:00 to 3:30 PM ET |
| Lynch, L. | Treatment Experience in Adult Patients with Hypophosphatasia (HPP): Results of a US Survey | Poster Session I, Abstract #SAT-482, 10 October 2026, 2:00 to 3:30 PM ET |
| Ohata, Y. | Clinical Course and Candidate Biomarkers in Perinatal Hypophosphatasia | Poster Session I, Abstract #SAT-483, 10 October 2026, 2:00 to 3:30 PM ET |
| Padidela, R. | Diagnostic Delay and Clinical Burden in Hypophosphatasia: Results from a Cross-Sectional, Multinational, Mixed-Methods Study | Poster Session I, Abstract #SAT-481, 10 October 2026, 2:00 to 3:30 PM ET |
| Dhaliwal, R. | A Real-World US Survey Study Characterizing the Holistic Disease Burden in Adults with Hypophosphatasia | Poster Session II, Abstract #SUN-480, 11 October 2026, 2:00 to 3:30 PM ET |
| Tanfous, M. | Cascade Diagnosis of the Rare Metabolic Disease Hypophosphatasia (HPP) Within Families: A Case Series | Poster Session II, Abstract #SUN-492, 11 October 2026, 2:00 to 3:30 PM ET |
| Dahir, K. | Efficacy and Safety of Alkaline Phosphatase (ALP) Enzyme Replacement Therapy (ERT) Efzimfotase Alfa in Adolescents and Adults with Hypophosphatasia (HPP): Results of HICKORY as Part of a Three-Trial Phase 3 Clinical Program | Oral Presentation, Abstract #1116, 11 October 2026, 5:00 to 5:12 PM ET |
Chronic hypoparathyroidism
| Lead author | Abstract title | Presentation details |
|---|---|---|
| Vizcaya, D. | Chronic Hypoparathyroidism in the US: Prevalence and Incidence From 2018 to 2024, With Baseline Clinical Characteristics | Welcome Reception and Plenary Poster Session, Abstract #FRI-005, 9 October 2026, 5:30 to 7:15 PM ET; Poster Session I, Abstract #SAT-005, 10 October 2026, 2:00 to 3:30 PM ET |
| Siggelkow, H. | Leveraging Structured and Unstructured EHR Data to Improve Treatment and Clinical Context Capture in Chronic Hypoparathyroidism | Poster Session I, Abstract #SAT-015, 10 October 2026, 2:00 to 3:30 PM ET |
| Siggelkow, H. | Bone Manifestations in Chronic Hypoparathyroidism: A Retrospective Cohort Study | Poster Session I, Abstract #SAT-019, 10 October 2026, 2:00 to 3:30 PM ET |
| Khan, A. | Balanced Effects of Eneboparatide on Skeletal Parameters: Results From a Phase 3, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Eneboparatide in Adults With Chronic Hypoparathyroidism (CALYPSO) | Oral Presentation, Abstract #1089, 11 October 2026, 12:06 to 12:18 PM ET |
| Erdmann, M. | Methodological Differences Limit the Feasibility of an Indirect Treatment Comparison Between the Phase III CALYPSO (Eneboparatide) and PaTHway (Palopegteriparatide) Trials in Chronic Hypoparathyroidism | Late Breaking Poster Session II, Abstract #SUN-519, 11 October 2026, 2:00 to 3:30 PM ET |
| Vizcaya, D. | Epidemiology of Low Bone Density and Osteoporosis in Chronic Hypoparathyroidism: Baseline Prevalence and Medication Usage from National US Claims | Poster Session II, Abstract #SUN-014, 11 October 2026, 2:00 to 3:30 PM ET |
Related Topics and Keywords
Alexion, ASBMR 2026, hypoparathyroidism, hypophosphatasia
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy
